Navigation Links
Lumenis' UltraPulse TotalFX Treatment Featured on ABCNews 20/20 as a Secret Weapon for Treating for Burn Scars
Date:7/20/2009

uch as deep wrinkles and unwanted pigment, Dr. Waibel discovered that this system could also be used to treat burn scars. The UltraPulse laser uses two different methods of treating the skin as well as a unique delivery to stimulate new collagen growth, lighten dark colors on the scar and remove some of the scar tissue.

"We literally take the scar out, and as a result new collagen is stimulated and formed. We not only improve the scar -- we create new healthy skin where there was a scar," explained Dr. Waibel. "We are able to treat scars that we were never able to treat before."

"Lumenis is excited to support the triplets' treatments along with Dr. Waibel's exciting work in scar revision, but most importantly to provide hope for Chandra, Trae and Jordan where they had no options before," stated Mr. Dov Ofer, CEO of Lumenis. "The company is grateful for the significant efforts of all of the physicians and nurses at the Palm Beach Aesthetic Dermatology & Laser Center especially that of Dr. Waibel and Dr. Kenneth Beer its founder".

"The significant improvement in the appearance of the triplets' scars has generated profound interest in using UltraPulse technology in improving the quality of life for burn survivors around the globe. The treatment offers hope for many since it is far less traumatic than traditional surgical revision of scars, results can be seen within a few weeks and the skin continues to improve for up to six months following treatment," added Mr. Robert Mann, SVP and General Manager of Lumenis Aesthetic Business.

Motivated to share their success with others, Chandra, Trae and Jordan have also started a foundation to help burn survivors cover the cost of their treatments which is called "Three For Hope" (read more about the Berns Triplets www.bernstriplets.com and the Ultrapulse treatments featur
'/>"/>

SOURCE Lumenis Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Lumenis High Speed LightSheer(R) Duet(TM) Featured in New York Times Fashion & Style for Eliminating Pain and Nuisance of Hair Removal for Men
2. Lumenis Completes $15 Million Equity Financing From New and Existing Investors
3. Lumenis High Speed LightSheer(R) Duet(TM) Featured on ABCs Good Morning America Health as the New Gold Standard for Laser Hair Removal
4. Lumenis(R) Presents the SlimLine(TM) GI Laser Fiber: The Latest Advancement in Laser Lithotripsy for Gastroenterology
5. Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show
6. Lumenis Introduces the HoLEP Simulator and the PolyScope Disposable Ureteroscope at American Urology Association 2009 Annual Meeting
7. Lumenis(R) UltraPulse CO2 Laser to be Featured on National Television with Live Pearly Penile Papules (PPP) Procedure
8. Lumenis(R) UltraPulse CO2 Laser to be Featured on National Television with Live Pearly Penile Papule (PPP) Procedure
9. Lumenis(R) Introduces LightSheer(R) Duet(TM) for High Speed Permanent Hair Reduction
10. Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
11. Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 According to the National Institutes of ... epidermal necrolysis (TEN) that affects the skin and mucous membranes. ... under the age of 30 (i). In the early ... fever. As SJS advances, it affects the mucous membranes ... anus. Inflammation of the eye causes conjunctivitis (pink eye). ...
(Date:5/24/2013)... BEACH, CA (PRWEB) May 24, 2013 ... health care education community, proudly participated in festivities surrounding ... April 19-21. The event provided the perfect backdrop to ... facilities at 236 E. 3rd Street, housed in an ... Arts Building. , ACC was an active exhibitor throughout ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- About one in ... their teens take up smoking, drinking or illicit drug ... too bad, say experts at the Substance Abuse and ... that parents are actually one of the most influential ... issues. "Surveys of teens repeatedly show that ...
(Date:5/24/2013)... May 2013, Paris, France: Routinely measuring fractional flow ... angiography for diagnosis of chest pain leads to ... four patients, according to results from a study ... routine pressure wire assessment influence management strategy at ... was designed to assess whether routine assessment of ...
(Date:5/24/2013)... youth and diabetes keeps getting worse. The latest data from ... Type 2 diabetes are at high risk to develop heart, ... than people who acquire Type 2 diabetes as adults. ... to be at very high risk for early complications when ... endocrinology in the School of Medicine at The University of ...
Breaking Medicine News(10 mins):Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:American Career College Revs Up Community Support During Toyota Grand Prix of Long Beach 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:Youth with type 2 diabetes at much higher risk for heart, kidney disease 2
... CHAPEL HILL, N.C., May 27 As the ... companies are looking,for ways to up-sell and cross-sell ... the need for such practices, Best Practices LLC ... from less than 5% of their,service calls., ...
... NY/LOS ANGELES, CA: Stand Up To Cancer ... philanthropic dollars for accelerating ground-breaking research, launches today ... networks, entertainment industry executives, celebrities and prominent leaders ... CBS and NBC will donate one hour of ...
... TUCSON, Ariz., May 27 Medipacs, Inc., a ... is has secured an,initial financial investment of $1.65 ... Venture Partners and other investors in Tucson, San,Diego, ... Mark McWilliams comments: "We are very pleased with,the ...
... IMTEC Corporation proudly,introduces a newly redesigned version ... works in conjunction with IMTEC,s proprietary,FlashCT(R) software for ... scanner, Vision provides users with tools for viewing, ... may be in the form of,a raw scan ...
... in Melanoma , Mutations in the p14ARF tumor ... independent of the effect of the p16 gene. , ... on chromosome 9 that is frequently mutated in melanomas. ... p16 tumor suppressor gene occurs frequently in melanomas, it ...
... days off, poor-quality output, study finds , , TUESDAY, May ... hyperactivity disorder (ADHD) miss, on average, more than three ... new global reckoning of the problem. , Altogether, between ... ADHD, according to survey data from the World Health ...
Cached Medicine News:Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 2Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 3Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 4Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 5Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 6Health News:IMTEC Introduces New Vision Software 2Health News:Also in the May 27 JNCI 2Health News:Also in the May 27 JNCI 3Health News:Also in the May 27 JNCI 4Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 2Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 3
(Date:5/24/2013)... and BOSTON , May 24, 2013 /PRNewswire/ ... development company, is pleased to announce that it has engaged Mr ... the Company,s business development capabilities in Japan ... 15 years of experience in business development, licensing and alliance management ... Roche Pharma ( Japan ), Nippon Roche and Tanabe ...
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... May 23, 2013  Haemonetics Corporation (NYSE: HAE ... CFO & EVP-Business Development, will present at The Deutsche Bank ... Boston, MA on May 29, 2013 at ... ) The public may access Mr. Lindop,s presentation ... About Haemonetics Haemonetics (NYSE: HAE ) ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... 21, 2010 /PRNewswire-FirstCall/ – ERT (Nasdaq: ERES ... the pharmaceutical, biotechnology and medical device industries, today confirmed ... of Dr. Michael J. McKelvey, its President and CEO, ... currently ERT,s Chairman and Chief Scientific Officer, has also ...
... 21, 2010 PTC Therapeutics, Inc. announced today that ... trial of ataluren, an investigational new drug, in patients ... http://photos.prnewswire.com/prnh/20010919/PTCLOGO) The 48-week study is designed to ... with nmCF.  The trial has enrolled 238 patients at ...
Cached Medicine Technology:ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 2ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 2PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 4
... is designed to play a key ... research involves proteomics, cytomics or genomics. ... enhanced firmware, powerful Optima eXPert software ... L-XP delivers superior functionality, optimized user ...
... integrated chemistry system brings versatility in ... smaller laboratory. A model of innovation ... chemistry system features state-of-the-art Dimension testing ... environment, in a flexible. affordable, easy-to-use ...
The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability....
... convenience make the RD/Hitachi 902 the ... workload laboratory. Compact, sample selective clinical ... 26 tests on board (including 3 ... tests per hour respectively up to ...
Medicine Products: